Saltar al contenido
MilliporeSigma
Todas las fotos(1)

Key Documents

View All Documentation

SML2419

Sigma-Aldrich

GSK690

≥98% (HPLC)

Sinónimos:

(R)-4-(5-(Pyrrolidin-3-ylmethoxy)-2-(p-tolyl)pyridin-3-yl) benzonitrile), (R)-4-(5-(Pyrrolidin-3-ylmethoxy)-2-p-tolylpyridin-3-yl)benzonitrile, 4-(2-(4-Methylphenyl)-5-((3R)-3-pyrrolidinylmethoxy)-3-pyridinyl)benzonitrile, GSK 354, GSK 690, GSK-354, GSK-690, GSK354

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C24H23N3O
Número de CAS:
2101305-84-2
Peso molecular:
369.46
UNSPSC Code:
12352200

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

N#CC1=CC=C(C2=CC(OC[C@H]3CNCC3)=CN=C2C4=CC=C(C)C=C4)C=C1

Biochem/physiol Actions

GSK690 (GSK354) is a cell-permeable pyrrolidinylmethoxypyridine-based compound that inhibits lysine-specific demethylase 1 (LSD1; KDM1A) in a potent and reversible manner (IC50 = 90 nM) without affecting MAO-A activity (IC50 >200 μM). GSK690 is shown to induce the expressions of CD86 (EC50 = 1.4 μM in THP1 cells) and LY96 (EC50 = 423 nM in MV4-11 cells), and prevent adipogenesis in murine preadipocyte cultures.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Daniel P Mould et al.
Journal of medicinal chemistry, 60(19), 7984-7999 (2017-09-12)
Inhibition of lysine specific demethylase 1 (LSD1) has been shown to induce the differentiation of leukemia stem cells in acute myeloid leukemia (AML). Irreversible inhibitors developed from the nonspecific inhibitor tranylcypromine have entered clinical trials; however, the development of effective
Tinka Haydn et al.
Cell death & disease, 8(6), e2879-e2879 (2017-06-16)
The lysine-specific demethylase 1 (LSD1) is overexpressed in several cancers including rhabdomyosarcoma (RMS). However, little is yet known about whether or not LSD1 may serve as therapeutic target in RMS. We therefore investigated the potential of LSD1 inhibitors alone or
Alba Maiques-Diaz et al.
Cell reports, 22(13), 3641-3659 (2018-03-29)
Pharmacologic inhibition of LSD1 promotes blast cell differentiation in acute myeloid leukemia (AML) with MLL translocations. The assumption has been that differentiation is induced through blockade of LSD1's histone demethylase activity. However, we observed that rapid, extensive, drug-induced changes in transcription occurred
Development and evaluation of selective, reversible LSD1 inhibitors derived from fragments
Hitchin JR, Blagg J, Burke R .
Medicinal Chemistry, 1513-1522 (2013)
John P McGrath et al.
Cancer research, 76(7), 1975-1988 (2016-02-04)
Lysine-specific demethylase 1 (KDM1A) is a transcriptional coregulator that can function in both the activation and repression of gene expression, depending upon context. KDM1A plays an important role in hematopoiesis and was identified as a dependency factor in leukemia stem
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico